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Background: Burkholderia pseudomallei, the causative agent of melioidosis, is endemic to Southeast Asia and
northern Australia. Clinical manifestations of disease are diverse, ranging from chronic infection to acute
septicaemia. The current gold standard of diagnosis involves bacterial culture and identification which is time
consuming and often too late for early medical intervention. Hence, rapid diagnosis of melioidosis is crucial for the
successful management of melioidosis.
Methods: The study evaluated 4 purified B. pseudomallei recombinant proteins (TssD-5, Omp3, smBpF4 and
Omp85) as potential diagnostic agents for melioidosis. A total of 68 sera samples from Malaysian melioidosis
patients were screened for the presence of specific antibodies towards these proteins using enzyme-linked
immunosorbent assay (ELISA). Sera from patients with various bacterial and viral infections but negative for B.
pseudomallei, as well as sera from healthy individuals, were also included as non-melioidosis controls. The Mann
Whitney test was performed to compare the statistical differences between melioidosis patients and the non-
melioidosis controls.
Results: TssD-5 demonstrated the highest sensitivity of 71% followed by Omp3 (59%), smBpF4 (41%) and Omp85
(19%). All 4 antigens showed equally high specificity (89-96%). A cocktail of all 4 antigens resulted in slightly
reduced sensitivity of 65% but improved specificity (99%). Multiple-antigen ELISA provided improved sensitivity of
88.2% whilst retaining good specificity (96%). There was minimal reactivity with sera from healthy individuals
proposing the utility of these antigens to demarcate diseased from non-symptomatic individuals in an endemic
country.
Conclusions: TssD-5 demonstrated high detection sensitivity and specificity and the results were obtained within a
few hours compared to time consuming culture and IFAT methods commonly used in a clinical setting. The use of
multiple-antigens resulted in improved sensitivity (88.2%) whilst maintaining superior specificity. These data
highlight the use of TssD-5 and other recombinant antigens tested in this study as potential serodiagnostic agents
for melioidosis.
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Melioidosis is a severe community-acquired infectious dis-
ease caused by the Gram negative bacillus Burkholderia
pseudomallei. The bacterium is commonly found in soil
and water in Southeast Asia and northern Australia;
however, increasing cases of melioidosis have been
reported in other tropical regions and the bacterium is
now believed to present a serious global threat [1,2].
Clinical manifestations of melioidosis are extremely
diverse and vary from acute sepsis to chronic localised
pathology to latent infections which can reactivate
decades later [3,4]. In all series, the lung was the most
commonly affected organ, either presenting with cough
and fever resulting from a primary lung abscess or pneu-
monia, or secondary to septicaemic spread [5]. The overall
mortality rate in individuals infected with B. pseudomallei
range from 30-70%, depending on whether the patient is
septicaemic or not [5]. In northeast Thailand the
mortality rate is reported to be 50% (35% in children)
and 19% in Australia [3,6].
Melioidosis is treatable if detected early, however,
early medical intervention is hindered by two major fac-
tors; firstly, the definitive diagnosis involves bacterial
culture and identification which is time consuming and
often leads to a critical delay in antibiotic therapy and
successful management of the acute form of the disease
[7]. Secondly, B. pseudomallei is resistant to diverse
groups of antimicrobials including third generation
cephalosporins whilst quinolones and aminoglycosides
have no reliable effect [8,9]. Hence, a definitive and
rapid diagnosis is critical and vital prior to the adminis-
tration of ceftazidime or carbapenems as these antibi-
otics are generally not used as empirical treatment for
septicaemia in endemic regions. Culturing of bacteria
from clinical samples represents the diagnostic gold
standard for melioidosis [3,10]. Whilst it is simple,
reliable and economical, the long duration required to
reach a definitive diagnosis is a major drawback. The
most commonly used serological method, the indirect
hemagglutination test (IHA), is poorly standardised
worldwide. Moreover, IHA has limited clinical value in
regions of endemicity due to the high background anti-
body titres in healthy individuals, most likely the result
of repeated environmental exposure to B. pseudomallei
[11]. In addition, IHA uses crude whole-cell preparation
or bacterial lysates which may potentially lead to high
false-positive results. A critical limitation of this assay is
the lack of standardisation between laboratories with
respect to the antigens used, the antigens remain poorly
characterised and are likely to be variable between iso-
lates [12]. The indirect immune-fluorescence antibody
test (IFAT) using whole B. pseudomallei cells as antigen
was found to be sensitive and superior to IHA and
requires only a day to obtain the results [13]. The onlydrawback is that IFAT requires a fluorescence micro-
scope and skilled personnel which might not be readily
available in rural endemic regions of Southeast Asia.
Enzyme-linked immunosorbent assay (ELISA) and re-
lated serodiagnostic strategies are being considered
more favourably as rapid and reliable tools for definitive
diagnosis of melioidosis [14-16]. Various antigen prepa-
rations such as crude and purified exopolysaccharide
(EPS) and lipopolysaccharide (LPS) as well as recombin-
ant flagellin and Bip proteins have been reported as po-
tential diagnostic antigens in an ELISA format, however,
sensitive and reliable antigens are yet to be identified.
We have previously reported the characterisation of sev-
eral immunogenic B. pseudomallei recombinant proteins
including outer membrane protein A (Omp3), Omp85
and serine protease MprA (smBpF4) [17-19]. Recently,
Chieng et al. [20] described the elevated induction levels
of B. pseudomallei type VI secretion system HCP protein
(TssD-5) over a 6 hr infection period in human macro-
phages and preliminary analysis of the antigenicity of this
protein has indicated strong binding to antibodies in a
small cohort of melioidosis-confirmed patient sera
(Chieng et al. in preparation). All four recombinant pro-
teins are unique to Burkholderia spp. and interestingly,
TssD-5 is highly conserved in B. pseudomallei only
whilst the other recombinant proteins are conserved in
B. pseudomallei as well as in Burkholderia spp. such as
B. mallei and B. thailandensis. Thus, all the selected
proteins should demonstrate minimal cross reactivity
with sera from non-melioidosis individuals presenting
with other bacterial infections. Concomitantly, these 4
recombinant proteins were strongly reactive with
melioidosis patients’ or B. pseudomallei infected
animal sera [17-19]. As these B. pseudomallei recom-
binant proteins were patient sero-reactive proteins, we
attempt to evaluate their potential as suitable antigen(s)
for diagnosis of melioidosis by an ELISA-based screen, a
rapid diagnostic method to replace the conventional
gold standard which involves bacterial culture and is
time consuming.Methods
Bacterial strains and plasmids
The B. pseudomallei human isolate (strain D286) was
obtained from the Pathogen Laboratory, School of
Biosciences and Biotechnology, Faculty of Science and
Technology, Universiti Kebangsaan Malaysia. This strain
was isolated from a patient with clinical manifesta-
tions of melioidosis at the Kuala Lumpur Hospital
and previously characterised based on biochemical
tests as well as by 16S rRNA sequencing [21]. The recom-
binant B. pseudomallei constructs used in this study are
summarised in Table 1.
Table 1 Recombinant B. pseudomallei constructs used in this study
Recombinant constructs Gene ID Expressed protein molecular weight (kDa) References
Serine protease MprA, smBpF4 BPSS1993 55 [23]
Outer membrane protein A, Omp3 BPSL2522 27 [17]
Outer membrane protein, Omp85 BPSL2151 89 [18]
Type VI secretion system HCP protein, TssD-5 BPSS1498 22.9 Chieng et al. in preparation
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Collection and use of melioidosis sera samples from pa-
tients was approved by the Medical Ethics Committee,
University Malaya Medical Centre, Malaysia (Medical
Ethics Committee ref. no. 260.1). The patient samples
were taken as part of standard patient care. A total of 68
sera samples from culture-confirmed [22] or indirect
IFAT-confirmed [13] melioidosis patients from Malaysia
presenting with acute and chronic disease manifesta-
tions were screened. The detection of total antibodies to
melioidosis by IFAT was performed as previously de-
scribed [13]. A cut-off value of 1:80 was used to differenti-
ate between true infections from background titres due to
basal antibody levels in endemic areas [13]. A summary of
the ethnic distribution of the sampled individuals is
provided in Table 2.
Sera (n = 29) from individuals presenting with vari-
ous bacterial and viral infections (Legionella (n = 6),
Mycoplasma (n = 5), Leptospira (n = 4), Chlamydia (n = 4),
endemic typhus (n = 3), typhoid (n = 3), scrub typhus
(n = 2), dengue (n = 1) and Chikugunya (n = 1)) but
confirmed B. pseudomallei-negative were used as disease
controls. Control sera from healthy and confirmed HIV-
negative individuals (n = 61) were generously provided by




Gender Male 53 (77.9)
Female 12 (17.6)
Unknown 3 (4.4)








Unknown 18 (26.5)Preparation of B. pseudomallei lysate
B. pseudomallei D286 lysate was prepared as previously
described with minor modifications [21]. Briefly,
B. pseudomallei D286 was grown in brain heart infusion
(BHI) broth overnight at 37°C and the overnight culture
was centrifuged at 4,000 × g for 20 min at 4°C. The
bacterial pellets obtained were washed twice with PBS.
The cell suspension was heat-killed at 80°C for 1 hr and
subsequently disrupted by sonication for 15 min on ice
(Vibracell, Sonics and Materials). The lysate was then
quantified by the Bicinchoninic Acid assay.Over-expression and purification of recombinant B.
pseudomallei proteins
Over-expression and purification of recombinant B.
pseudomallei Omp3 [17], Omp85 [18] and smBpF4
proteins [23] were performed as previously described.
For TssD-5, the corresponding coding region of tssD-5
was amplified by polymerase chain reaction from the
B. pseudomallei D286 genomic DNA as previously
described [17]. The primer pairs used were TssD-5_F
(CACCATGCTGGCCGGAATATA) and TssD-5_R
(TCAGCCATTCGTCCAGTTTG) designed based on
the B. pseudomallei K96243 annotated ORF. Thirty
cycles of amplification were performed according to
the manufacturer’s recommended protocol using
Expand High Fidelity PCR system (Roche) with an
annealing temperature of 53.2°C. The purified PCR
product was cloned into pET 200/D-TOPOW according
to the manufacturer’s recommendation (Invitrogen).
Gene orientation and sequences were verified by DNA
sequencing. Recombinant B. pseudomallei TssD-5 pro-
teins were expressed as soluble proteins in Escherichia
coli BL21 (DE3) Star at 37°C with 1 mM isopropyl-β-
D-thiogalactoside (IPTG) for 5 hrs. Expression cultures
were harvested and bacterial pellets were re-suspended
in BugBusterW Protein Extraction Reagent (Novagen).
The suspension was incubated at room temperature
for 20 min with rotation, then centrifuged at 12,000 × g
for 30 min at 4°C and the supernatant was collected.
The expressed soluble recombinant TssD-5 protein
was purified under native conditions through the
HisTrap HP 1 ml column on the AKTAPurifier system
(GE, Healthcare) according to the manufacturer’s
recommended protocol (Chieng et al. in preparation).
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ELISA was performed in CELLSTAR 96 Well Polystyr-
ene Flat Bottom Microplates (Greiner Bio One) as
previously described with minor modifications [17,18].
Wells were coated overnight at 4°C with 0.25 μg per
well of purified recombinant B. pseudomallei proteins
or B. pseudomallei D286 lysate in coating bicarbonate
buffer (0.1 M sodium bicarbonate, pH 9.6) in a 100 μl
final volume. For the antigen cocktail, 4 recombinant
proteins (0.25 μg each) were mixed in coating bicar-
bonate buffer (0.1 M sodium bicarbonate, pH 9.6) in a
100 μl final volume and coated in individual wells. All
the antigens were initially denatured at 80°C for 10
min before coating of wells. Following overnight incu-
bation, wells were washed 5 times with distilled water
and blocked with blocking buffer [5% (w/v) skim milk
in PBS] for 1 hr at 37°C. After 5 washes with distilled
water, triplicate wells were incubated at 37°C for 1 hr
with various human sera samples diluted (1:1600) in
blocking buffer to a volume of 100 μl. Following incu-
bation, wells were washed 5 times with distilled water
and incubated at 37°C for 1 hr with 100 μl of rabbit
anti-human IgG conjugated with peroxidase (1:10,000
diluted in blocking buffer, Sigma-Aldrich). Subse-
quently, 100 μl ABTS:peroxidase B (1:1; KPL) was
added as substrate. The reaction was left to develop for
30 min at room temperature. The absorbance was
measured at 405 nm with an automated Sunrise ELISA
reader (Tecan). The mean and standard deviations of
repeated measurements were calculated for each tested
specimen. The cut-off point was determined as the
mean of the 61 healthy controls plus 2 standard devia-
tions. Analysis of the single antigen ELISA results was
performed as previously described [14,24]. Briefly, each
serum sample was considered positive if the mean
absorbance was greater than the cut-off point. For the
multiple-antigen ELISA results, single antigen ELISA
data was re-evaluated and the serum tested was deter-
mined to be positive according to the following
criteria: (1) any 2 or more antigens specifically react
with serum with the absorbance greater than the cut-
off value calculated from the mean absorbance
(A405nm) plus 2 standard deviations of healthy controls
or (2) any antigen that specifically reacts with serum
when the cut-off value was calculated from the mean
absorbance (A405nm) plus 3 standard deviations of
healthy controls [25].Statistical analysis
Statistical analysis on human sera reactivity was
performed using the Mann Whitney test within the
GraphPad PrismW version 4.0 (GraphPad Software)
software package.Results
Evaluation of recombinant proteins as serodiagnostic
reagents
The 4 purified recombinant proteins, TssD-5, Omp3,
Omp85 and smBpF4, were used in an ELISA to detect
antigen-specific IgG in culture confirmed or IFAT con-
firmed melioidosis sera as well as in B. pseudomallei-
negative disease control sera and healthy individuals
(non-melioidosis).
The majority (70%) of sera samples from culture- or
IFAT- confirmed individuals used in this study were from
the Malay ethnic group (Table 2). The incidence of meli-
oidosis in other ethnic groups such as Chinese and Indians
(13% each) appeared to be less frequent compared to the
Malay group. The male to female ratio was 4.42 to 1. The
number of males outnumbering females is consistent with
other studies on the epidemiology of melioidosis in
Malaysia: Pahang state (3.6:1) [22] and Alor Setar, Kedah
state (3.03:1) [26]. In addition, 62% of the sera samples
were from patients aged between 30–70 years. The human
sera were tested against B. pseudomallei lysate by ELISA
prior to performing the screen with the recombinant
proteins. All 68 melioidosis patients’ sera reacted with
B. pseudomallei lysate whilst the non-melioidosis control
sera showed no reactivity (data not shown), demonstrating
the sensitivity of ELISA screening.
All 4 recombinant B. pseudomallei proteins demon-
strated varying sensitivity but good specificity (Table 3
and Figure 1). In brief, TssD-5 when used as a single
antigen demonstrated the highest sensitivity in both
culture confirmed (62%) and IFAT confirmed (85%)
samples with an average of 71% and good specificity
(96%) with a cut-off value of 0.1094, the lowest amongst
the 4 antigens. Omp3 demonstrated moderate sensitiv-
ity of 50% in culture confirmed samples and 73% in
IFAT confirmed samples with average of 59% with good
specificity (90%) and the cut-off value was 0.1387.
smBpF4 also demonstrated moderate but slightly lower
sensitivity of 41% on average (38% in culture confirmed
and 46% in IFTA confirmed samples, respectively) with
good specificity (89%) and its cut-off value was 0.1269.
Omp85 demonstrated the lowest sensitivity (19%) in
both culture and IFTA confirmed samples but good
specificity (96%) with its cut-off value calculated at
0.203. When all the 4 antigens were combined at equal
ratios, this cocktail formulation demonstrated some-
what lower sensitivity of 65% on average (64% in culture
confirmed and 65% in IFAT confirmed samples, respect-
ively) compared to TssD-5 alone but improved specifi-
city (99%). To predict the potential value of combining
these 4 antigens under optimal conditions, we used 2
different criteria (Table 3) [25] to analyse the individual
reactivity of TssD-5, Omp3, smBpF4 and Omp85 with
the sera. By adopting these criteria, the detection
Table 3 ELISA results for melioidosis confirmed and control sera
Recombinant proteins Cut-off Sensitivity (%)
(no. positive/total no.*)
Specificity (%)






(n = 42) (n = 26) (n = 68)
TssD-5 (type VI secretion system HCP protein) 0.1094 62 (26/42) 85 (22/26) 71 (48/68) 96 (4/90)
Omp3 (outer membrane protein A) 0.1387 50 (21/42) 73 (19/26) 59 (40/68) 90 (9/90)
smBpF4 (serine protease MprA) 0.1269 38 (16/42) 46 (12/26) 41 (28/68) 89 (10/90)
Omp85 (outer membrane protein) 0.2030 19 (8/42) 19 (5/26) 19 (13/68) 96 (4/90)
Cocktails of 4 recombinant proteins§ 0.1936 64 (27/42) 65 (17/26) 65 (44/68) 99 (1/82**)
Multiple antigens combination (all 4 recombinant proteins‡) 88.2 (60/68) 96 (4/90)
* melioidosis confirmed sera by ELISA against B. pseudomallei lysate.
† non-melioidosis sera [healthy control (n = 61) and disease control (n = 29)].
** non-melioidosis sera [healthy control (n = 59) and disease control (n = 23)].
§ Cocktail of 4 recombinant proteins used to coat a single well.
‡ The single antigen ELISA data was re-evaluated and different criteria were used to calculate sensitivity and specificity. The serum tested was determined to be
melioidosis positive according to the following criteria: (1) any 2 or more antigens specifically react with serum with the absorbance greater than the cut-off value
calculated from the mean absorbance (A405nm) plus 2 standard deviations of healthy controls or (2) any antigen that specifically reacts with serum when the
cut-off value was calculated from the mean absorbance (A405nm) plus 3 standard deviations of healthy controls.
Figure 1 Reactivity of human sera with 4 recombinant B. pseudomallei proteins. Purified recombinant (A) TssD-5, (B) Omp3, (C) smBpF4
and (D) Omp85 were screened against melioidosis patients’ (n = 68, solid circle), healthy control (n = 61, solid square) and disease control (n = 29,
solid triangle) sera. Each symbol represents the average of triplicate readings of one serum sample. Shown is a representative of 2 independent
experiments. Cut-off values indicated by dashed line. Significance determined using the Mann Whitney test (***P-value < 0.0001; **P-value
< 0.001; *P-value < 0.01).
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the specificity (96%). Great variation in antibody bind-
ing towards the same antigen was observed and this was
particularly obvious for TssD-5 where the absorption
values of individual sera ranged from 0.11 to 2.0 and to
the lesser extent against Omp3 (0.145-1.2). The mean
absorbance of all 4 recombinant proteins was signifi-
cantly higher in melioidosis patients sera compared to
non-melioidosis sera (Figure 1).
Discussion
A recent study reported the true sensitivity of culture as
a diagnostic tool as 60% [27]. Thus, there is critical need
for a fast, easy and accurate diagnostic assay for meli-
oidosis as well as to differentiate individuals with active
infection from those previously exposed to the bacteria,
particularly in endemic countries [28]. Recombinant
proteins as diagnostic antigens offer many advantages
over the use of bacterial cells including eliminating
health risks to laboratory personnel and reducing incon-
sistent antigen preparation [28]. Therefore, the use of
recombinant proteins as potential diagnostic antigens
via an ELISA detection-based screen were evaluated but
with varying results. Recombinant-truncated flagellin
was tested by ELISA as a diagnostic antigen and demon-
strated high sensitivity and specificity (93.8% and 96.3%,
respectively) [14], but only a limited number of samples
from non-endemic regions was used. BipB and BipD
were also evaluated as antigens by screening samples
from 2 endemic regions, Thailand and Australia. How-
ever, neither of them demonstrated better diagnostic
accuracy than the IHA [16].
In this study, TssD-5 demonstrated the highest sensi-
tivity (71%) and good specificity (96%) within the cohort
of sera samples. Furthermore, TssD-5 demonstrated
minimal antibody response in healthy controls as com-
pared to the other 3 antigens with only one weakly
positive response observed in disease controls. This
species-specific feature is valuable in endemic regions
where high sero-positivity in healthy individuals poses a
challenge to accurate diagnosis of melioidosis [29].
Omp3, on the other hand, demonstrated only moderate
sensitivity (59%) although an earlier study on the same
protein reported higher sensitivity (95%) [30], which
may be attributed to different cut-off values used. In our
study, control sera were obtained from a cohort of
Malaysian individuals and therefore classified as from
an endemic region. As such, it is not surprising that
baseline sero-positivity (cut-off value) was high in the
healthy population indicating possible previous expos-
ure to B. pseudomallei. Of the previously reported
immunogenic proteins, smBpF4 and Omp85 exhibited
moderate to poor sensitivity of 41% and 19%, respectively,
but showed good specificity (89-96%). Nonetheless, a PCRassay targeting the mprA gene of B. pseudomallei demon-
strated 100% sensitivity and specificity in detecting the
gene in clinical samples [31,32]. This suggests that whilst
the mprA (smBpF4) gene may be a good bioindicator of
B. pseudomallei by PCR, the protein may be unsuitable
for serodiagnosis of melioidosis.
The evaluation of a cocktail of 4 proteins gave an im-
provement in specificity (99%) but the sensitivity (65%)
was somewhat lower than TssD-5 alone (Table 3 and
Figure 1). This finding was unexpected as the combination
of antigens was predicted to improve the sensitivity or be
equally sensitive as TssD-5. A similar finding was reported
by Lyashchenko et al. [33] where combinatorial cocktails
of 4 or 8 antigens resulted in significant loss of sensitivity
for detection of Mycobacterium tuberculosis compared to
the use of a single antigen. This reduced sensitivity may
be explained by the limited protein binding capacity of
the polystyrene solid phase in the microtitre plate,
resulting in the reduced display of epitopes or proteins
competing with each other for binding to polystyrene
which may result in larger proteins swathing their
smaller counterparts [33].
Zhang et al. [25] demonstrated that the heterogeneous
antibody response to different antigens could be utilised
to increase the sensitivity of diagnosis. This laid the foun-
dation for the development of a multiple-antigen ELISA
system for screening of tuberculosis with improved sensi-
tivity and specificity over conventional diagnostic methods
[25]. We used a similar approach by combining the 4
antigens, to achieve an improved sensitivity from 71%
using a single antigen to 88.2% whilst retaining good
specificity (96%).
Using a B. pseudomallei protein microarray, Felgner
et al. [34] identified 49 potential serodiagnostic antigens
for melioidosis including Omp3 confirming the poten-
tial of Omp3 as a candidate antigen. However, to date,
none of these antigens have been proposed as a sensitive
or specific diagnostic tool for melioidosis. A large num-
ber of these serodiagnostic proteins were classified as
extracellular or outer membrane proteins as predicted
by the computational annotation PSORTb and most of
them are encoded on Chromosome 2 of B. pseudomallei
K96243. TssD-5 satisfies both criteria and in addition,
the up-regulation of the TssD-5 gene transcript during
the bacteria’s adaptation to the intracellular environment
proposes that TssD-5 is a potentially better biomarker
candidate for diagnosis of melioidosis. Furthermore, our
study suggests that protein size may be an important fac-
tor to consider when identifying sensitive sero-diagnostic
antigens. TssD-5 (22.9 kDa) and Omp3 (27 kDa) demon-
strated better diagnostic values compared to the larger
proteins, smBpF4 (55 kDa) and Omp85 (85 kDa). Indeed,
among 49 potential diagnostic proteins for melioidosis
reported by Felger et al., more than a half were < 60 kDa
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reported as sensitive diagnostic antigens for tuberculosis
[25], acute leptospirosis [35] and Brucella abortus infec-
tion [36]. In summary, the present study demonstrated
that TssD-5 is a potentially superior diagnostic candidate
for melioidosis.
Conclusions
We screened 4 recombinant B. pseudomallei proteins as
potential diagnostic markers for melioidosis in an
ELISA system. The recombinant Type VI secretion
system protein TssD-5, achieved 71% sensitivity and
96% specificity, which is superior to the culture method
with a recently reported sensitivity of 60%. The use of a
multiple-antigen ELISA demonstrated better sensitivity
(88.2%) while retaining good specificity (96%). Thus,
TssD-5 in combination with the other 3 recombinant
proteins tested demonstrated good potential as safe and
sensitive serodiagnostic agents for melioidosis.
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